Announcement
Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the Article
Posted in the last 24 hours
Fresh from the desks
fair-lending
The Mortgage Industry Sues New Jersey Over the Country's Broadest Lending Rule
The Mortgage Bankers Association is asking a federal court to strike down New Jersey's disparate impact regulations, arguing the rule forces lenders into race-conscious decision-making that federal fair lending law forbids.
banking
A Challenger Bank Goes Up for Sale, and Its Best Feature Is a Legal Cloud
Nationwide and Investec are preparing first-round bids for Aldermore, the UK lender FirstRand is selling after the motor finance misselling scandal pushed provisions to 750 million pounds and forced a rethink of its British business.
stablecoins
The Stablecoin Boom's Next Prize Is the Most Boring Mile
Fin.com emerged from stealth with a $20 million seed round led by Garrett Camp's Expa to build the infrastructure that converts stablecoins into local bank balances across 51 countries, the unglamorous step every stablecoin product depends on.
oncology
GSK Bets Up to $750 Million That a Preclinical Drug Can Fix Blood Cancer Therapy's Hardest Problem
GSK is acquiring global rights to a trispecific T cell engager from Shanghai's Chimagen Biosciences for multiple myeloma, a deal aimed at the tolerability problems that have kept powerful TCE drugs to late-line use.
microbiome
Europe's Regulators Reject a Microbiome Therapy, Not Its Science, but Its Trial Design
The EMA's CHMP maintained a negative trend vote on MaaT Pharma's MaaT013 for acute graft-versus-host disease, faulting the absence of a randomized controlled trial, with a formal opinion due September 18.
psychiatry
A Psychedelic Drug Clears Its Third Phase 3 Trial, This Time for Anxiety
Definium Therapeutics reported positive topline results from the Panorama study of DT120, its LSD-derived oral treatment, with a placebo-adjusted 5.1-point improvement on the anxiety scale and an NDA filing planned for 2027.
targeted-therapy
The Trial Won and the Stock Lost. The Lung Cancer Data Behind Both
Zipalertinib plus chemotherapy extended median progression-free survival to 14.5 months versus 8.5 in first-line EGFR exon 20 NSCLC, a six-month gain that met its primary endpoint, while Cullinan shares fell on cross-trial comparisons.
immunotherapy
In a Lung Cancer Where Survival Rarely Passes a Year, One Drug Nearly Doubled It
BioNTech and OncoC4's gotistobart produced median overall survival of 18.5 months versus 10.0 months for chemotherapy in previously treated squamous NSCLC, data presented at the World Conference on Lung Cancer.
obesity
The Obesity Market Gets a Tolerability Play, and It Is Not a GLP-1
Corbus Pharmaceuticals reported positive Phase 1b data for oral CRB-913, a CB1 inverse agonist that produced up to 5 percent weight loss in 12 weeks with a safety profile the company argues compares well against approved oral obesity drugs.
B2B Research
Most Popular Research Articles
Intent Data
Intent Data Providers For B2B
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
Knowledge Management
Knowledge Management Solutions
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
MDR
Managed Detection And Response Services
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
MDR Europe
Managed Detection And Response Services In Europe
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Manufacturing Tech
Manufacturing Technology Services
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Market Intelligence
Market And Competitive Intelligence Platforms
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Open Banking
Open Banking Intermediaries
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Change Management
Organizational Change Management Services
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
PLM
Product Lifecycle Management Platforms For Discrete Manufacturers
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Announcements
News from Mavengity
Announcement
James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article
Browse by topic
Where would you like to start?
Every article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Insurance
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceMortgage
Rates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgagePersonal Finance
Budgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceLegal
Contracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealthcare & Medical
Health coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareResearch
Gartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse Research
Why Mavengity
Editorial standards you can check
Independently researched
We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
Plain-English explanations
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
Straight, not slanted
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Written for readers, not lenders
Mavengity is reader-supported and editorially independent from the products we cover.